Literature DB >> 31265503

Erratum: Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-195.

.   

Abstract

[This corrects the article DOI: 10.1182/blood-2014-05-552729.].

Year:  2016        PMID： 31265503      PMCID： PMC5025902          DOI： 10.1182/blood-2016-07-730689

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  22 in total

1.  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Authors:  Jeremy S Abramson; Tanya Siddiqi; Jacob Garcia; Christine Dehner; Yeonhee Kim; Andy Nguyen; Sophie Snyder; November McGarvey; Matthew Gitlin; Corey Pelletier; Monika P Jun
Journal:  Blood Adv       Date:  2021-03-23

2.  Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia.

Authors:  Pratik A Patel; Shanmuganathan Chandrakasan; Geoffrey E Mickells; Inci Yildirim; Carol M Kao; Carolyn M Bennett
Journal:  Pediatrics       Date:  2020-05-04       Impact factor: 7.124

3.  Chimeric antigen receptor-T cells with cytokine neutralizing capacity.

Authors:  Adrian H J Tan; Natasha Vinanica; Dario Campana
Journal:  Blood Adv       Date:  2020-04-14

4.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Authors:  Jennifer N Brudno; Irina Maric; Steven D Hartman; Jeremy J Rose; Michael Wang; Norris Lam; Maryalice Stetler-Stevenson; Dalia Salem; Constance Yuan; Steven Pavletic; Jennifer A Kanakry; Syed Abbas Ali; Lekha Mikkilineni; Steven A Feldman; David F Stroncek; Brenna G Hansen; Judith Lawrence; Rashmika Patel; Frances Hakim; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

5.  Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.

Authors:  Joshua A Hill; Elizabeth M Krantz; Kevin A Hay; Sayan Dasgupta; Terry Stevens-Ayers; Rachel A Bender Ignacio; Merav Bar; Joyce Maalouf; Sindhu Cherian; Xueyan Chen; Greg Pepper; Stanley R Riddell; David G Maloney; Michael J Boeckh; Cameron J Turtle
Journal:  Blood Adv       Date:  2019-11-26

6.  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Authors:  Mazyar Shadman; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Filippo Milano; Ang Li; Alexandre V Hirayama; Mohamed L Sorror; Sindhu Cherian; Xueyan Chen; Ryan D Cassaday; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; David G Maloney; Cameron J Turtle
Journal:  Blood Adv       Date:  2019-10-22

Review 7.  Practical aspects of building a new immunotherapy program: the future of cell therapy.

Authors:  Jesús G Berdeja
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Authors:  Nirali N Shah; Steven L Highfill; Haneen Shalabi; Bonnie Yates; Jianjian Jin; Pamela L Wolters; Amanda Ombrello; Seth M Steinberg; Staci Martin; Cindy Delbrook; Leah Hoffman; Lauren Little; Anusha Ponduri; Haiying Qin; Haris Qureshi; Alina Dulau-Florea; Dalia Salem; Hao-Wei Wang; Constance Yuan; Maryalice Stetler-Stevenson; Sandhya Panch; Minh Tran; Crystal L Mackall; David F Stroncek; Terry J Fry
Journal:  J Clin Oncol       Date:  2020-04-14       Impact factor: 44.544

9.  Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.

Authors:  Daniel A Lichtenstein; Fiorella Schischlik; Lipei Shao; Seth M Steinberg; Bonnie Yates; Hao-Wei Wang; Yanyu Wang; Jon Inglefield; Alina Dulau-Florea; Francesco Ceppi; Leandro C Hermida; Kate Stringaris; Kim Dunham; Philip Homan; Parthav Jailwala; Justin Mirazee; Welles Robinson; Karen M Chisholm; Constance Yuan; Maryalice Stetler-Stevenson; Amanda K Ombrello; Jianjian Jin; Terry J Fry; Naomi Taylor; Steven L Highfill; Ping Jin; Rebecca A Gardner; Haneen Shalabi; Eytan Ruppin; David F Stroncek; Nirali N Shah
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

10.  Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant.

Authors:  Monzr M Al Malki; Ni-Chun Tsai; Joycelynne Palmer; Sally Mokhtari; Weimin Tsai; Thai Cao; Haris Ali; Amandeep Salhotra; Shukaib Arslan; Ibrahim Aldoss; Nicole Karras; Chatchada Karanes; Jasmine Zain; Samer Khaled; Anthony Stein; David Snyder; Guido Marcucci; Stephen J Forman; Ryotaro Nakamura
Journal:  Blood Adv       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.